Zobrazeno 1 - 10
of 117
pro vyhledávání: '"James J Gibbons"'
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
The key pharmacokinetic (PK) parameters (Supplemental Table 3) at the recommended phase 2 dose of 225 mg show that food has minimal impact on absorption of ensartinib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a449be1d3575a45fbdf7a486b35dea41
https://doi.org/10.1158/1078-0432.22464930
https://doi.org/10.1158/1078-0432.22464930
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Supplemental Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b6a5679d59d795489c267075719ba7
https://doi.org/10.1158/1078-0432.22464939
https://doi.org/10.1158/1078-0432.22464939
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Supplemental Figure 1. Representative example from one patient showing the rash that was most frequently observed with ensartinib. The white arrow in the top figure points to the rash that is circled in the bottom figure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f66975726db644fb04183f8f0be7ce6
https://doi.org/10.1158/1078-0432.22464948
https://doi.org/10.1158/1078-0432.22464948
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
The mean concentration of ensartinib in plasma and skin at multiple time points after a single dose of 50 mg/kg is listed in Supplemental Table 2. At 12 hours post-dose, the concentration of ensartinib was 9.0 higher in the skin than in the plasma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2310314dfceff9b78f3fb2b814227f16
https://doi.org/10.1158/1078-0432.22464933
https://doi.org/10.1158/1078-0432.22464933
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Ensartinib was tested against wild-type ALK and 17 ALK variants in the Reaction Biology panel. Ensartinib potently inhibited all evaluated ALK variants, with in vitro IC50s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbdd2f4b84f588464781c1ddfcb5713b
https://doi.org/10.1158/1078-0432.22464936
https://doi.org/10.1158/1078-0432.22464936
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Supplemental Figure 2. Arithmetic mean concentration-time curves for fasted patients receiving 225 mg of ensartinib on Days 1 and 22 of Cycle 1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f98c8efd389aa1126d66dd5df38527
https://doi.org/10.1158/1078-0432.22464945
https://doi.org/10.1158/1078-0432.22464945
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Supplemental Figure 3. Best percentage change from baseline in sum of target lesions is presented for the ALK-positive evaluable patients at 200 mg who had received prior crizotinib and as second-generation ALK TKI. Dashed lines indicate RECIST v1.1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c9ac478e7fd9b0d6f29a51bfb45a096
https://doi.org/10.1158/1078-0432.22464942
https://doi.org/10.1158/1078-0432.22464942
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Purpose: Evaluate safety and determine the recommended phase II dose (RP2D) of ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), and evaluate preliminary pharmacokinetics and antitumor activity in a first-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ccddeb80bdd472b4ab2d76bc559c22
https://doi.org/10.1158/1078-0432.c.6525870.v1
https://doi.org/10.1158/1078-0432.c.6525870.v1
Autor:
Ker Yu, James J. Gibbons, Robert T. Abraham, Jessica Lucas, Lourdes Toral-Barza, Wei-Guo Zhang, Boris Shor
Supplementary Table 1, Figures 1-2 Legends from A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::825dc0453ff9c0a7660d83dd6f63aa96
https://doi.org/10.1158/0008-5472.22374927.v1
https://doi.org/10.1158/0008-5472.22374927.v1
Autor:
James J. Gibbons, Semiramis Ayral-Kaloustian, Carolyn Discafani, Thai Nguyen, Judy Lucas, Danielle Vitale, Richard Hernandez, Nan Zhang, Carl F. Beyer
5-Chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine butanedioate (TTI-237) is a microtubule-active compound of novel structure and function. Structurally, it is one
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16ac1bf6199fe9d451e181b4e511fa7d
https://doi.org/10.1158/0008-5472.c.6496545
https://doi.org/10.1158/0008-5472.c.6496545